-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a...
IN THE SPOTLIGHT
-
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
Aiming for a Cure: How CD74 Research Could Eliminate Drug-Resistant Lung Cancer for Good
Lung cancer remains the leading cause of cancer death worldwide. Over the past two decades, the development of targeted therapies, particularly tyrosine kinase inhibitors (TKIs)... -
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community. -
6 Tips for Managing Scanxiety
Read time: 4 minutes. Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as...
Natural alkaloids as potential EGFR allosteric inhibitors: DFT, molecular docking, and molecular dynamics approach
Natural alkaloids as potential EGFR allosteric inhibitors: DFT, molecular docking, and molecular dynamics approach
Interpreting Overall Survival and CNS Outcomes in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Interpreting Overall Survival and CNS Outcomes in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Evolving First Line Treatment Goals in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Evolving First Line Treatment Goals in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
EGFR/TP53 共突变、大量胸腔积液，奥希替尼联合化疗一线治疗晚期肺癌患者获完全缓解_腾讯新闻
Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review
Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review
The network pharmacology prediction and experiment validation of Astragalus membranaceus for alleviating silicosis fibrosis via decreasing MMP9 and EGFR expression
The network pharmacology prediction and experiment validation of Astragalus membranaceus for alleviating silicosis fibrosis via decreasing MMP9 and EGFR expression
Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR
LncRNA EGFR-AS1 inhibits ferroptosis to reduce radiosensitivity of cervical cancer through the m6A/IGF2BP3/APAF1 axis
LncRNA EGFR-AS1 inhibits ferroptosis to reduce radiosensitivity of cervical cancer through the m6A/IGF2BP3/APAF1 axis
Correction: Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy
Correction: Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy